USP1 knockdown or ML323 treatment reduced the expression of PCNA, cyclin D1 and cyclin E1, which meant that targeting USP1 could decrease the proliferation of HCC cells via cell cycle arrest. Here, USP1 is linked to hepatocellular carcinoma.